AGIOS PHARMACEUTICALS

Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress

12 May 2022 10:00:00 By Nasdaq GlobeNewswire

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022

10 May 2022 07:00:05 By Nasdaq GlobeNewswire

Agios Reports Business Highlights and First Quarter 2022 Financial Results

05 May 2022 07:00:03 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022

21 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

14 Apr 2022 08:34:52 By Nasdaq GlobeNewswire

Agios to Participate in March Investor Conferences

28 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Agios Reports Fourth Quarter and Full Year 2021 Financial Results

24 Feb 2022 07:00:03 By Nasdaq GlobeNewswire

Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

17 Feb 2022 15:41:11 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022

10 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases

10 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

22 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

13 Dec 2021 18:15:00 By Nasdaq GlobeNewswire

Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition

13 Dec 2021 10:30:00 By Nasdaq GlobeNewswire

Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at 63rd ASH Annual Meeting and Exposition

13 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Agios Appoints Richa Poddar as Chief Commercial Officer

15 Nov 2021 16:01:00 By Nasdaq GlobeNewswire

Agios to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 63rd ASH Annual Meeting and Exposition

04 Nov 2021 09:00:01 By Nasdaq GlobeNewswire

Agios Reports Business Highlights and Third Quarter 2021 Financial Results

03 Nov 2021 07:10:58 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021

21 Oct 2021 16:01:00 By Nasdaq GlobeNewswire

Agios To Present at September Investor Conferences

30 Aug 2021 07:00:00 By Nasdaq GlobeNewswire

Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

17 Aug 2021 16:01:00 By Nasdaq GlobeNewswire